This content is from: Home

Interview Kalon Biotherapeutics: The future of genes and nanotech

Andrew Strong, previously general counsel at Texas A&M and now at Kalon Biotherapeutics, talks to Simon Crompton about his new facility, gene patents and employee inventions

To access our in-house intelligence please request a trial here.

Read this article – and more – for a 30 day period.


Are you already an Managing IP subscriber? Login here


Instant access to all of our content. Membership Options | 30 Day Trial